NovaBridge Biosciences (NBP) Gains from Investment Securities (2019 - 2024)
NovaBridge Biosciences (NBP) posted quarterly Gains from Investment Securities of -$2.0 million for Q3 2024, down 133.47% quarter-over-quarter from -$846360.5 in Q4 2020.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Gains from Investment Securities (2019 - 2024) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Gains from Investment Securities for 3 consecutive years, with -$2.0 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Gains from Investment Securities changed N/A year-over-year to -$2.0 million; the TTM figure through Dec 2024 stood at -$2.8 million (changed N/A YoY), while the FY2025 annual figure was $11.6 million, up 183.6% from the prior year.
- Gains from Investment Securities slipped to -$2.0 million in Q3 2024 per NBP's latest filing, from -$846360.5 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at -$846360.5 in Q4 2020 and bottomed at -$2.0 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | -1.98 Mn |
| Dec 31, 2020 | -1.30 Mn |
| Dec 31, 2019 | -4,965.83 |
| Sep 30, 2019 | 5.46 Mn |